(S)-tert-butyl 3-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate | 500213-34-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-tert-butyl 3-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
• 英文别名: N-((S)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-L-phenylalanine methyl ester；N-(3S-2-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-L-phenylalanine methyl ester；Boc-Tic-Phe-OMe；tert-butyl (3S)-3-[[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]carbamoyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate
• CAS: 500213-34-3
• 化学式: C₂₅H₃₀N₂O₅
• 分子量: 438.524
• InChiKey: BZJRJMCTLDIZHU-SFTDATJTSA-N

物化性质

• 熔点：
  91-93 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  615.3±55.0 °C(Predicted)
• 密度：
  1.189±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-tert-butyl 3-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 在 盐酸 、 三乙胺 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 241.5h， 生成 (S)-2-((S)-3,3-dimethyl-1-oxo-10,10a-dihydroimidazo[1,5-b]isoquinolin-2(1H,3H,5H)-yl)-3-phenylpropanoic acid methyl ester
  参考文献：
  名称：

  2-Substituted (S)-2-(3,3-dimethyl-1-oxo-10,10a-dihydroimidazo[1,5-b]isoquinolin-2(1H,3H,5H)-yl)acetic acids: Conformational prediction, synthesis, anti-thrombotic and vasodilative evaluation

  摘要：

  (S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid (TIC) can inhibit thrombosis by inhibiting platelet aggregation. The investigation of amino acids modified TIC reveals that a stretching conformation is critical for high anti-thrombotic activity. The conformational modeling shows that introducing a ring into amino acid modified TIC results in a desirable stretching conformation. According to this hypothesis, we synthesized seventeen novel 2-substituted (S)-2-(3,3-dimethyl-1-oxo-10,10a-dihydroimidazo[1,5-b] isoquinolin-2(1H,3H,5H)-yl)acetic acids (5a-q). In the in vitro anti-platelet aggregation assay, for ADP-induced platelet aggregation the IC50 values of 5a-q are 1.8-3.4-folds lower than that of TIC. In the in vivo anti-thrombotic assay, the effective dose of 5a-q was 167-folds lower than that of TIC. The vessel strip assay showed that 5a-q had mild vasorelaxation activity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.12.005
• 作为产物：
  描述：

  (S)-(-)-1,2,3,4-四氢异喹啉-3-羧酸 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 60.0h， 生成 (S)-tert-butyl 3-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
  参考文献：
  名称：

  2-Substituted (S)-2-(3,3-dimethyl-1-oxo-10,10a-dihydroimidazo[1,5-b]isoquinolin-2(1H,3H,5H)-yl)acetic acids: Conformational prediction, synthesis, anti-thrombotic and vasodilative evaluation

  摘要：

  (S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid (TIC) can inhibit thrombosis by inhibiting platelet aggregation. The investigation of amino acids modified TIC reveals that a stretching conformation is critical for high anti-thrombotic activity. The conformational modeling shows that introducing a ring into amino acid modified TIC results in a desirable stretching conformation. According to this hypothesis, we synthesized seventeen novel 2-substituted (S)-2-(3,3-dimethyl-1-oxo-10,10a-dihydroimidazo[1,5-b] isoquinolin-2(1H,3H,5H)-yl)acetic acids (5a-q). In the in vitro anti-platelet aggregation assay, for ADP-induced platelet aggregation the IC50 values of 5a-q are 1.8-3.4-folds lower than that of TIC. In the in vivo anti-thrombotic assay, the effective dose of 5a-q was 167-folds lower than that of TIC. The vessel strip assay showed that 5a-q had mild vasorelaxation activity. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.12.005

文献信息

• A progressive synthetic strategy for class B synergimycins
  作者：Jennifer L. Robinson、Rachel E. Taylor、Lisa A. Liotta、Megan L. Bolla、Enrique V. Azevedo、Irene Medina、Shelli R. McAlpine

  DOI：10.1016/j.tetlet.2004.01.048

  日期：2004.3

  four macrocyclic peptides that are the core structure of class B synergimycins, and the synthesis of a final class B derivative. Our synthetic route to these synergimycin derivatives allows the incorporation of amino acid substitutions at all points in the macrocycle, leading to structurally diverse class B analogs.

  描述了作为B类协同霉素核心结构的四个大环肽的合成，以及最终的B类衍生物的合成。我们对这些协同霉素衍生物的合成途径允许在大环的所有点上引入氨基酸取代，从而导致结构上多样化的B类类似物。
• A class of novel N-(3S-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-l-amino acid derivatives: their synthesis, anti-thrombotic activity evaluation, and 3D QSAR analysis
  作者：Shenling Cheng、Xiaoyi Zhang、Wei Wang、Ming Zhao、Meiqing Zheng、Heng Wei Chang、Jianghui Wu、Shiqi Peng

  DOI：10.1016/j.ejmech.2009.08.002

  日期：2009.12

  To find new anti-thrombotic agents, a natural amino acid was introduced into the 3-position of anti-platelet aggregation active 3S-tetrahydroisoquinoline-3-carboxylic acid (THIQA), and 20 novel dipeptide derivatives, 3S-tetrahydroisoquinoline-3-carboxyamino acids (6a–t), targeting the intestinal peptide transport system were provided. In vitro anti-platelet aggregation assay of 6a–t indicated that

  为了找到新的抗血栓形成剂，将天然氨基酸引入了抗血小板聚集活性3 S-四氢异喹啉-3-羧酸（THIQA）的3位，以及20种新型二肽衍生物3 S-四氢异喹啉-3提供了靶向肠肽转运系统的-羧基氨基酸（6a - t）。6a - t的体外抗血小板凝集试验表明，它们抑制二磷酸腺苷（ADP），花生四烯酸（AA），血小板活化因子（PAF）和凝血酶（TH）诱导的血小板凝集的效力高于THIQA和6a – t的体内抗血栓形成测定提示它们在大鼠中抑制血栓形成的能力也高于THIQA。根据基于MFA的Cerius2 QSAR模块，使用训练/测试集6a，b，d，g – p / 6c，e，f，q和训练/测试集6a – p / 6q – t，两个方程式（r， 0.984和0.996）建立了与6a - t的体内或体外活性相关的结构。
• Design, synthesis and biological evaluation of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors
  作者：Xiaopan Zhang、Jian Zhang、Lei Zhang、Jinghong Feng、Yingying Xu、Yumei Yuan、Hao Fang、Wenfang Xu

  DOI：10.1016/j.bmc.2011.08.041

  日期：2011.10

  A series of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives were designed, synthesized and assayed for their activities against aminopeptidase N (APN/CD13) and MMP-2. The results showed that most compounds exhibited higher inhibitory activities against APN than that of MMP-2. Within this series, compound 12h (IC50 = 6.28 ± 0.11 μM) showed similar inhibitory activities compared with

  设计，合成并测定了一系列新颖的1,2,3,4-四氢异喹啉-3-羧酸衍生物对氨基肽酶N（APN / CD13）和MMP-2的活性。结果表明，大多数化合物对APN的抑制活性均高于MMP-2。在该系列中，化合物12h（IC 50  = 6.28±0.11μM）与Bestatin（IC 50  = 5.55± 0.01μM）表现出相似的抑制活性，并且可以用作新型APN抑制剂作为抗癌剂，用于未来的APN抑制剂开发。
• Novel antibiotics: C-2 symmetrical macrocycles inhibiting Holliday junction DNA binding by E. coli RuvC
  作者：Po-Shen Pan、Fiona A. Curtis、Chris L. Carroll、Irene Medina、Lisa A. Liotta、Gary J. Sharples、Shelli R. McAlpine

  DOI：10.1016/j.bmc.2006.03.028

  日期：2006.7.15

  Holliday junctions (HJs) are formed as transient DNA intermediates during site-specific and homologous recombination. Both of these genetic exchange pathways are critical for normal DNA metabolism and repair. Trapping HJs leads to bacterial cell death by preventing proper segregation of the resulting interlinked chromosomes. Macrocyclic peptides designed to target this intermediate were synthesized with the goal of identifying compounds with specificity for this unique molecular target. We discovered ten macrocycles, both hexameric and octameric peptides, capable of trapping HJs in vitro. Those macrocycles containing tyrosine residues proved most effective. These data demonstrate that C-2 symmetrical macrocycles offer excellent synthetic targets for the development of novel antibiotic agents. Furthermore, the active compounds identified provide valuable tools for probing different pathways of recombinational exchange. (c) 2006 Elsevier Ltd. All rights reserved.
• Novel antibiotics: second generation macrocyclic peptides designed to trap Holliday junctions
  作者：Lisa A. Liotta、Irene Medina、Jennifer L. Robinson、Chris L. Carroll、Po-Shen Pan、Ricardo Corral、Jennifer V.C. Johnston、Kristina M. Cook、Fiona A. Curtis、Gary J. Sharples、Shelli R. McAlpine

  DOI：10.1016/j.tetlet.2004.09.084

  日期：2004.11

  Described are the syntheses of 15 macrocyclic peptides designed to trap Holliday junctions (HJs) in bacteria during site-specific and homologous recombination. This leads to inhibiting bacterial growth. These second generation macrocycles were based on the C-2 symmetrical HJ. They were synthesized using a strategy that permits elucidation of the amino acid role in binding HJs. The syntheses of these macrocycles are an important step in the development of a new class of antibiotics. (C) 2004 Elsevier Ltd. All rights reserved.